The purpose of this clinical study is to evaluate the safety and effectiveness of combination therapy with two investigational (experimental) drugs, 1592U89 and 141W94, and 1 FDA-approved drug, DMP-266 (Sustivea) in patients infected with HIV who have detectable levels of HIV virus in their blood even after combination therapy that included an HIV protease inhibitor.
Showing the most recent 10 out of 782 publications